These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16926592)

  • 1. Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients.
    Satoh S; Tada H; Murakami M; Tsuchiya N; Li Z; Numakura K; Saito M; Inoue T; Miura M; Hayase Y; Suzuki T; Habuchi T
    Transplantation; 2006 Aug; 82(4):486-93. PubMed ID: 16926592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Suzuki T; Habuchi T
    Ther Drug Monit; 2008 Feb; 30(1):46-51. PubMed ID: 18223462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
    Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
    Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Kagaya H; Inoue K; Miura M; Satoh S; Saito M; Tada H; Habuchi T; Suzuki T
    Eur J Clin Pharmacol; 2007 Mar; 63(3):279-88. PubMed ID: 17211619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Inoue K; Miura M; Satoh S; Kagaya H; Saito M; Habuchi T; Suzuki T
    Ther Drug Monit; 2007 Jun; 29(3):299-304. PubMed ID: 17529886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
    van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Schmidt J; Budde K; Kuypers D; Le Meur Y; van der Werf M; Mamelok R; van Gelder T
    Clin Pharmacol Ther; 2009 Sep; 86(3):319-27. PubMed ID: 19494809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.
    Satoh S; Tada H; Murakami M; Tsuchiya N; Inoue T; Togashi H; Matsuura S; Hayase Y; Suzuki T; Habuchi T
    Transplant Proc; 2005 May; 37(4):1751-3. PubMed ID: 15919454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-transplant mycophenolate mofetil pharmacokinetics in Mexican children.
    Villa M; González R; García-Roca P; Hernández AM; Ortiz L; Castañeda-Hernández G; Medeiros M
    Proc West Pharmacol Soc; 2011; 54():66-8. PubMed ID: 22423584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients.
    Kagaya H; Miura M; Satoh S; Inoue K; Saito M; Inoue T; Habuchi T; Suzuki T
    J Clin Pharm Ther; 2008 Apr; 33(2):193-201. PubMed ID: 18315786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR; de Jonge H; Naesens M; de Loor H; Halewijck E; Dekens M; Vanrenterghem Y
    Clin Ther; 2008 Apr; 30(4):673-83. PubMed ID: 18498916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection.
    Tada H; Satoh S; Iinuma M; Shimoda N; Murakami M; Hayase Y; Kato T; Suzuki T
    J Clin Pharmacol; 2003 Aug; 43(8):859-65. PubMed ID: 12953343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
    Cortinovis M; Gotti E; Pradini S; Gaspari F; Perico N
    Transplantation; 2011 Sep; 92(5):550-6. PubMed ID: 21709602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
    Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI
    Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients.
    Okamoto M; Wakabayashi Y; Higuchi A; Kadotani Y; Ogino S; Ushigome H; Akioka K; Kaihara S; Yoshimura N
    Transplant Proc; 2005 Mar; 37(2):859-60. PubMed ID: 15848556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.